Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Simulations Plus Inc's Business Segments
Simulations Plus Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q3 FY2026
Reportable Segments
2
Largest Segment
Software
Total Revenue
$ 22
Regions Reported
3
Revenue Share by Reportable Segment - Q3 FY2026
- Software57.6%
- Services42.4%
Revenue by Reportable Segment - Q3 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Software | $ 13 | 57.6% |
| Services | $ 9 | 42.4% |
Revenue Share by Region - Q3 FY2026
- Americas73.4%
- EMEA16.4%
- Asia Pacific10.2%
Revenue by Geographic Region - Q3 FY2026
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Americas | $ 16 | 73.4% |
| EMEA | $ 4 | 16.4% |
| Asia Pacific | $ 2 | 10.2% |
Revenue by Product & Service Category - Q3 FY2026
- License and Maintenance57.6%
- Development44.8%
- Service42.4%
- Discovery11.3%
- Clinical Operations1.3%
- Commercialization0.2%
Revenue by Product & Service Category - Q3 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| License and Maintenance | $ 13 | 57.6% |
| Development | $ 10 | 44.8% |
| Service | $ 9 | 42.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
3 more categories available
Sign in to unlock the full Simulations Plus Inc dataset.
Description of Simulations Plus Inc
Simulations Plus Inc. is a leading provider of simulation and modeling software and consulting services for the pharmaceutical, biotechnology, and other industries. The company was founded in 1996 and is headquartered in Lancaster, California, United States.
Simulations Plus specializes in the development and commercialization of advanced software tools that facilitate data analysis, modeling, and simulation of complex systems. Their flagship software products include GastroPlus, DDDPlus, MembranePlus, and ADMET Predictor.
GastroPlus is a premier simulation software used in pharmaceutical research and development to predict the absorption, distribution, metabolism, and elimination of drugs in humans. It simulates both the physiological and chemical processes that occur in the human gastrointestinal tract and other relevant tissues.
DDDPlus, another key product of Simulations Plus, is used for in-vitro dissolution experiments and helps in predicting the release of drugs from various dosage forms. It is widely adopted by pharmaceutical companies for formulation development and optimization.
MembranePlus is a tool designed to evaluate the permeability of molecules across biological membranes, which is crucial in drug design and development. It simulates the transport processes across cell membranes and predicts the rate of absorption of drugs.
ADMET Predictor is a software that uses predictive models to estimate the absorption, distribution, metabolism, excretion, and toxicity properties (ADMET) of drugs. It aids in the early stages of drug discovery and helps researchers make informed decisions based on quantitative data.
Simulations Plus' software products are based on quantitative structure-activity relationship (QSAR) modeling techniques and utilize various algorithms and databases to predict and analyze the behavior of drugs and other chemicals in complex biological systems.
In addition to software products, the company offers consulting services to pharmaceutical and biotechnology companies to assist them in utilizing the software effectively. Their team of experts provides training, technical support, and custom software development to address specific client needs.
The customer base of Simulations Plus encompasses the pharmaceutical industry, government agencies, and academic institutions. The software is used in various stages of drug development, from early discovery to post-marketing surveillance.
Simulations Plus operates on a subscription-based revenue model and generates revenue from software licensing, consulting services, and maintenance contracts.
The company holds a strong position in the market due to its robust software products, extensive expertise, and commitment to innovation. Their products have been validated and widely accepted by the scientific community, with numerous peer-reviewed publications citing the use of Simulations Plus software.
In summary, Simulations Plus Inc. is a well-established company that offers cutting-edge simulation and modeling software and consulting services to the pharmaceutical industry. Their products aid in drug discovery and development, helping researchers make informed decisions and optimize their processes.
Simulations Plus specializes in the development and commercialization of advanced software tools that facilitate data analysis, modeling, and simulation of complex systems. Their flagship software products include GastroPlus, DDDPlus, MembranePlus, and ADMET Predictor.
GastroPlus is a premier simulation software used in pharmaceutical research and development to predict the absorption, distribution, metabolism, and elimination of drugs in humans. It simulates both the physiological and chemical processes that occur in the human gastrointestinal tract and other relevant tissues.
DDDPlus, another key product of Simulations Plus, is used for in-vitro dissolution experiments and helps in predicting the release of drugs from various dosage forms. It is widely adopted by pharmaceutical companies for formulation development and optimization.
MembranePlus is a tool designed to evaluate the permeability of molecules across biological membranes, which is crucial in drug design and development. It simulates the transport processes across cell membranes and predicts the rate of absorption of drugs.
ADMET Predictor is a software that uses predictive models to estimate the absorption, distribution, metabolism, excretion, and toxicity properties (ADMET) of drugs. It aids in the early stages of drug discovery and helps researchers make informed decisions based on quantitative data.
Simulations Plus' software products are based on quantitative structure-activity relationship (QSAR) modeling techniques and utilize various algorithms and databases to predict and analyze the behavior of drugs and other chemicals in complex biological systems.
In addition to software products, the company offers consulting services to pharmaceutical and biotechnology companies to assist them in utilizing the software effectively. Their team of experts provides training, technical support, and custom software development to address specific client needs.
The customer base of Simulations Plus encompasses the pharmaceutical industry, government agencies, and academic institutions. The software is used in various stages of drug development, from early discovery to post-marketing surveillance.
Simulations Plus operates on a subscription-based revenue model and generates revenue from software licensing, consulting services, and maintenance contracts.
The company holds a strong position in the market due to its robust software products, extensive expertise, and commitment to innovation. Their products have been validated and widely accepted by the scientific community, with numerous peer-reviewed publications citing the use of Simulations Plus software.
In summary, Simulations Plus Inc. is a well-established company that offers cutting-edge simulation and modeling software and consulting services to the pharmaceutical industry. Their products aid in drug discovery and development, helping researchers make informed decisions and optimize their processes.
Simulations Plus, Inc. is a leading provider of simulation and modeling software primarily focused on the pharmaceutical and biotechnology industries. The company offers a range of products and services designed to facilitate drug discovery, development, and regulatory submission processes. Below is a comprehensive overview of the segments, products, and services offered by Simulations Plus:
Segments
1. Pharmaceutical Industry: This is the primary focus of Simulations Plus, catering to companies engaged in the research and development of new drugs. Their tools are invaluable for predicting properties of compound interactions and biological behavior.
2. Biotechnology Industry: Similar to the pharmaceutical segment but often focused more on biologics, the biotechnology segment leverages Simulations Plus products to optimize the design and efficacy of biologically-derived drugs.
3. Academia and Research Institutes: The company also serves academic institutions by providing software tools for teaching and research purposes, ensuring that the next generation of pharmacologists and biochemists are equipped with the necessary skills to utilize these simulations effectively.
Products
1. ADMET Predictor: This software evaluates the Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties of potential drug candidates based on their chemical structure. It incorporates quantitative structure-activity relationships (QSAR) to aid in predicting how compounds will behave in biological systems.
2. GastroPlus: A comprehensive modeling platform that simulates the pharmacokinetics and pharmacodynamics of drug compounds. This software assists in understanding how drugs move through the body and their varying effects based on different dosing scenarios. It is widely used for predicting oral absorption, metabolism, and drug-drug interactions.
3. PKSIM and MoBi: These tools are focused on physiologically-based pharmacokinetic (PBPK) modeling. PKSIM provides a framework for PBPK modeling, while MoBi offers an integrated environment for model building and simulation. Together, they enhance the understanding of how drugs interact with biological systems over time.
4. DILIsym: This is a specialized simulator for predicting drug-induced liver injury (DILI) risk. DILIsym uses mathematical modeling to simulate the biological processes leading to liver toxicity, allowing for better risk assessment during drug development.
5. MembranePac: This software is used for modeling the passive permeability of compounds through biological membranes, which is crucial for understanding absorption and bioavailability of drug candidates.
6. Kinetica: This product focuses on the analysis of pharmacokinetic/pharmacodynamic data and integrates with other Simulations Plus software to provide comprehensive predictive capabilities.
Services
1. Consultation Services: Simulations Plus provides expert consultation for clients needing assistance in model development and regulatory submission practices. This service includes input from experienced scientists who can help guide the simulation approach tailored to specific projects.
2. Training and Workshops: The company offers training programs and workshops for users of their software. These sessions are designed to enhance user proficiency and ensure that clients can maximize the utility of the products they have purchased.
3. Custom Software Development: Simulations Plus can also develop customized software solutions tailored to the specific needs and challenges of a client’s drug development processes.
4. Regulatory Support: The company provides services related to regulatory submissions, helping clients meet the necessary guidelines and requirements set by regulatory bodies such as the FDA and EMA.
5. Academic Collaborations: In alignment with their commitment to education, Simulations Plus engages in partnerships with academic institutions to develop new methodologies and enhance the teaching of pharmacodynamics and pharmacokinetics.
Summary
Simulations Plus, Inc. operates primarily within the life sciences sector, providing sophisticated simulation and modeling tools that streamline and enhance the drug development process. By offering products with state-of-the-art technology and comprehensive services, the company plays a vital role in improving the efficiency and efficacy of drug research and development for pharmaceutical and biotechnology companies worldwide. Their commitment to research and development ensures they remain at the forefront of simulation technology, continually evolving their offerings to meet the needs of a rapidly changing industry.
Segments
1. Pharmaceutical Industry: This is the primary focus of Simulations Plus, catering to companies engaged in the research and development of new drugs. Their tools are invaluable for predicting properties of compound interactions and biological behavior.
2. Biotechnology Industry: Similar to the pharmaceutical segment but often focused more on biologics, the biotechnology segment leverages Simulations Plus products to optimize the design and efficacy of biologically-derived drugs.
3. Academia and Research Institutes: The company also serves academic institutions by providing software tools for teaching and research purposes, ensuring that the next generation of pharmacologists and biochemists are equipped with the necessary skills to utilize these simulations effectively.
Products
1. ADMET Predictor: This software evaluates the Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties of potential drug candidates based on their chemical structure. It incorporates quantitative structure-activity relationships (QSAR) to aid in predicting how compounds will behave in biological systems.
2. GastroPlus: A comprehensive modeling platform that simulates the pharmacokinetics and pharmacodynamics of drug compounds. This software assists in understanding how drugs move through the body and their varying effects based on different dosing scenarios. It is widely used for predicting oral absorption, metabolism, and drug-drug interactions.
3. PKSIM and MoBi: These tools are focused on physiologically-based pharmacokinetic (PBPK) modeling. PKSIM provides a framework for PBPK modeling, while MoBi offers an integrated environment for model building and simulation. Together, they enhance the understanding of how drugs interact with biological systems over time.
4. DILIsym: This is a specialized simulator for predicting drug-induced liver injury (DILI) risk. DILIsym uses mathematical modeling to simulate the biological processes leading to liver toxicity, allowing for better risk assessment during drug development.
5. MembranePac: This software is used for modeling the passive permeability of compounds through biological membranes, which is crucial for understanding absorption and bioavailability of drug candidates.
6. Kinetica: This product focuses on the analysis of pharmacokinetic/pharmacodynamic data and integrates with other Simulations Plus software to provide comprehensive predictive capabilities.
Services
1. Consultation Services: Simulations Plus provides expert consultation for clients needing assistance in model development and regulatory submission practices. This service includes input from experienced scientists who can help guide the simulation approach tailored to specific projects.
2. Training and Workshops: The company offers training programs and workshops for users of their software. These sessions are designed to enhance user proficiency and ensure that clients can maximize the utility of the products they have purchased.
3. Custom Software Development: Simulations Plus can also develop customized software solutions tailored to the specific needs and challenges of a client’s drug development processes.
4. Regulatory Support: The company provides services related to regulatory submissions, helping clients meet the necessary guidelines and requirements set by regulatory bodies such as the FDA and EMA.
5. Academic Collaborations: In alignment with their commitment to education, Simulations Plus engages in partnerships with academic institutions to develop new methodologies and enhance the teaching of pharmacodynamics and pharmacokinetics.
Summary
Simulations Plus, Inc. operates primarily within the life sciences sector, providing sophisticated simulation and modeling tools that streamline and enhance the drug development process. By offering products with state-of-the-art technology and comprehensive services, the company plays a vital role in improving the efficiency and efficacy of drug research and development for pharmaceutical and biotechnology companies worldwide. Their commitment to research and development ensures they remain at the forefront of simulation technology, continually evolving their offerings to meet the needs of a rapidly changing industry.